Daklinza
Developed to alleviate chronic hepatitis C infection, indicated to target the virus and support sustained virologic response.
Strengths: 60mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Direct-acting antiviral
- Pharmacological class
NS5A inhibitor
- Contraindications
hypersensitivity to daclatasvir; concurrent use of strong inducers of CYP3A4
- Precautions and warnings
monitor liver enzymes during treatment
- Minor side effects
headache; fatigue; nausea
- Moderate side effects
anaemia; insomnia; diarrhoea
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
Continuous therapy
- Duration
12–24 weeks
- Storage instructions
Store in a cool dry place.
- Drug interactions
amiodarone; carbamazepine; phenytoin
- Age restrictions
Adults
Serious side effects
bradycardia — requires immediate medical attention; liver failure — requires immediate medical attention
Patient summary
Developed to alleviate chronic hepatitis C infection, indicated to target the virus and support sustained virologic response.
Mechanism of action
Daclatasvir inhibits the NS5A protein, which is essential for both viral RNA replication and virion assembly, thus preventing the virus from multiplying.
Pregnancy and breastfeeding
Pregnancy: Should not be used during pregnancy unless necessary. Breastfeeding: Avoid during treatment.
Daklinza
Developed to alleviate chronic hepatitis C infection, indicated to target the virus and support sustained virologic response.
Editorial Notes
- Active ingredient(s): Daclatasvir
- Listed indication(s): Chronic Hepatitis C
Available option
- 28 tablets - 60 mg863-60-mg-6366